<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153747</url>
  </required_header>
  <id_info>
    <org_study_id>5064</org_study_id>
    <nct_id>NCT04153747</nct_id>
  </id_info>
  <brief_title>High Radiofrequency Power for Faster and Safer Pulmonary Vein Ablation Trial (POWER FAST III)</brief_title>
  <acronym>POWER-FAST</acronym>
  <official_title>High-power Short-duration Radiofrequency Application for Faster and Safer Pulmonary Vein Ablation Trial (POWER FAST III Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter 1:1 randomized study. Two atrial fibrillation ablation strategies are compared:&#xD;
      1) conventional ablation using point-by-point radiofrequency applications with power 40 W&#xD;
      guided by LSI &gt; 6 or AI &gt; 500 on the anterior aspect of pulmonary veins and power 25 W guided&#xD;
      by LSI &gt;5 or AI &gt;350 on the posterior wall near the esophagus; 2) point-by-point RF&#xD;
      applications with power set at 70 W and duration 9-10 s. The main objective of the trial is&#xD;
      the incidence of esophageal lesions evaluated with systematic endoscopy and clinical efficacy&#xD;
      evaluated with daily ECG transtelephonic transmissions during 1-year follow-up. Secondary&#xD;
      objectives include total RF time and parameters of acute PV isolation efficacy (first-pass&#xD;
      isolation, acute reconnections and dormant conduction).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter 1:1 randomized study: Hospital Universitario La Paz, Madrid; Hospital Clínico&#xD;
      Universitario San Carlos, Madrid; Hospital Clínico y Provincial de Barcelona, Barcelona;&#xD;
      Complejo Hospitalario de Navarra, Pamplona; Hospital Clínico Universitario de Valladolid;&#xD;
      Hospital Clínico Universitario de Albacete; Hospital Clínico Universitario de Alicante;&#xD;
      Hospital Universitario Virgen de las Nieves, Granada; Hospital La Fe, Valencia; Hospital&#xD;
      Clínico de Valencia; Hospital Universitario Juan Ramón Jiménez, Huelva; Hospital de la&#xD;
      Ribera, Alzira, Valencia. España. Spain.&#xD;
&#xD;
      Two atrial fibrillation ablation strategies are compared: 1) conventional ablation using&#xD;
      point-by-point radiofrequency applications with power 40 W guided by LSI &gt; 6 or AI &gt; 500 on&#xD;
      the anterior aspect of pulmonary veins and power 25-40 W guided by LSI &gt;5 or AI &gt;350 on the&#xD;
      posterior wall near the esophagus; 2) point-by-point RF applications with power set at 70 W&#xD;
      and duration 9-10 s.&#xD;
&#xD;
      The main objective of the trial is the incidence of esophageal lesions evaluated with&#xD;
      systematic endoscopy and clinical efficacy evaluated with daily ECG transtelephonic&#xD;
      transmissions during 1-year follow-up. Secondary objectives include total RF time and&#xD;
      parameters of acute PV isolation efficacy (first-pass isolation, acute reconnections and&#xD;
      dormant conduction).&#xD;
&#xD;
      Subestudy: asymptomatic cerebral lesions detected by 1,5 T MRI &lt;72 h after ablation. Not all&#xD;
      centers participate in the subestydy. However, if the center participates, all patients in&#xD;
      both ablation groups will be included in the subestudy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2019</start_date>
  <completion_date type="Anticipated">April 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: incidence of esophageal thermal lesions</measure>
    <time_frame>24 hours after ablation (permissible up to 72 hours after ablation)</time_frame>
    <description>Incidence of thermal esophageal lesions evaluated by endoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: recurrene of atrial arrhythmias</measure>
    <time_frame>1 year</time_frame>
    <description>Recurrences of any atrial arrhythmias &gt;30 seconds during 1-year follow-up evaluated by daily transtelephonic ECG transmissions (at least 1 ECG/day and additional transmissions whenever the patient perceives arrhythmia-related symptoms).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radiofrequency time</measure>
    <time_frame>during ablation procedure</time_frame>
    <description>Total radiofrequency time required for complete pulmonary veins isolation (included acute intraprocedural reconnections and dormant conduction).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Catheter Ablation</condition>
  <arm_group>
    <arm_group_label>Conventional ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Point-by-point catheter-based pulmonary veins isolation using convencional radiofrequency parameters.&#xD;
Anterior aspect of pulmonary veins: 40 W, temperature limit 45 ºC, irrigation 17-30 ml/min; objective LSI&gt;=6 or Ablation index &gt;=500.&#xD;
Posterior aspect of pulmonary veins: 20-40 W, temperature limit 45 ºC, irrigation 17-3 ml/min; objective LSI&gt;=5 or Ablation index &gt;=350.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-power and short-duration ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Point-by-point catheter-based pulmonary veins isolation using high-power and short duration radiofrequency: 70 W, duration per application 9-10 s (initial ramp 2-3 s according to the technical characterictics of radiofrequency sources), temperature limit 45 ºC, irrigation 17 ml/min, contac-force &gt; 5 g.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High-power and short-duration radiofrequency ablatio (70 W / 9-10 s)</intervention_name>
    <description>Pulmonary veins electrical isolation: high-power and short-duration ablation</description>
    <arm_group_label>High-power and short-duration ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values</intervention_name>
    <description>Pulmonary veins electrical isolation: low-power ablation.</description>
    <arm_group_label>Conventional ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Esophageal endoscopy</intervention_name>
    <description>Esophageal endoscopy to detect postablation esophageal thermal lesions.</description>
    <arm_group_label>Conventional ablation</arm_group_label>
    <arm_group_label>High-power and short-duration ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Daily 30-seconds ECG</intervention_name>
    <description>Transtelephonic daily 30-seconds single lead electrocardiogram</description>
    <arm_group_label>Conventional ablation</arm_group_label>
    <arm_group_label>High-power and short-duration ablation</arm_group_label>
    <other_name>Transtelephonic daily 30-seconds single lead electrocardiogram</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Paroxysmal or persistent atrial fibrillation.&#xD;
&#xD;
          -  Currently accepted class I or II indication for ablation according to practice&#xD;
             guidelines: symptomatic arrhythmia, failure of at least 1 antiarrhythmic drug or&#xD;
             patient's manifest preference of ablation instead of drugs.&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Acceptance of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous pulmonary veins ablation of any type.&#xD;
&#xD;
          -  Permanent atrial fibrillation.&#xD;
&#xD;
          -  Heart surgery &lt;3 months before ablation.&#xD;
&#xD;
          -  Coronary revascularization of any type &lt;3 months before ablation.&#xD;
&#xD;
          -  Myocardial infarction or acute coronary syndrome &lt; 3 months before ablation.&#xD;
&#xD;
          -  Stroke or transient cerebral ischaemic attack &lt; 3 months before ablation.&#xD;
&#xD;
          -  Left atrial thrombus.&#xD;
&#xD;
          -  Contraindication for anticoagulation.&#xD;
&#xD;
          -  Absolute indication of double antiplatelet drugs.&#xD;
&#xD;
          -  Complex congenital heart disease, corrected or not.&#xD;
&#xD;
          -  Any clinical situation absolutely precluding an interventional procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José L Merino, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz, Madrid, España.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio C Castrejón-Castrejón, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz, Madrid, España.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Escobar Cervantes, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz, Madrid, España.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Consuelo Froilán Torres, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz, Madrid, España.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrés Fernández Prieto, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz, Madrid, España.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcel Martínez Cossiani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz, Madrid, España.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>José L Merino, PhD</last_name>
    <phone>+34 91 207 13 01</phone>
    <phone_ext>41301</phone_ext>
    <email>lapaz@arritmias.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergio Castrejón-Castrejón, PhD</last_name>
    <phone>+34 91 207 13 01</phone>
    <phone_ext>41301</phone_ext>
    <email>lapaz@arritmias.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital La Paz, Department of Cardiology</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose L Merino, PhD</last_name>
      <phone>+34 91 207 13 01</phone>
      <phone_ext>41301</phone_ext>
      <email>lapaz@arritmias.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 2, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Paz</investigator_affiliation>
    <investigator_full_name>Dr. Sergio Castrejón-Castrejón</investigator_full_name>
    <investigator_title>Electrophysiologist, Principal investigator (together with Dr. José Luis Merino)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

